Replies to post #2562 on BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Well I guess it (Europroteome) didn't work very well.

Europroteome, AG, a privately owned German company currently in insolvency proceedings.


Cancer Gene Therapy WeekWelcome to NewsRx!

Business Update
Company acquires rights for 16 cancer targets from Europroteome
June 13th, 2005

Genmab, A/S, announced that it has acquired rights to 16 potential targets to treat nonsteroid-dependent cancers of epithelial cell origin, such as gastrointestinal cancers, including colon cancer, from the insolvency administrator of Europroteome, AG, a privately owned German company currently in insolvency proceedings.
Genmab purchased all of Europroteome's rights, including patent applications and know-how, and does not owe anything further to the insolvency estate. There are no milestone or royalty obligations.

Genmab has started generating human antibodies to a unique target highly expressed on colon carcinomas.

"These rights give Genmab...

[erthang]

It looks like Abbott is partnering with this company in order to provide the technological expertise to integrate effective cancer biomarkers into their platform for breast cancer diagnostics. (I could be interpreting it wrong!)

"Data will be aligned with a panel of cancer markers from Abbott. Combinations of markers will be selected for further development and integration into Abbott's instrument platforms, used widely in hospitals and clinical laboratories throughout the world."

I suppose you would have to read the whole article in context. It does seem as though this company is in the business of researching, identifying biomarkers and technology integration.

I pose this question to the board, "how does this new Abbott partnership reflect on the licensing agreement with Biocurex? Could Abbott be including recaf as one of the "biomarkers to be aligned with data" from this company. Is the Abbott/Biocurex deal limited to prostate, or can Abbott use recaf technology in breast cancer diagnostics as well? Or would Abbott need to sign a new licensing agreement re:breast cancer? Could this new partnership provide the data from the outside source (or lead to write-ups in medical journals)Bocxman has been anticipating? I welcome as much feedback as possible (points of view), for the benefit of the board!